ZVSA vs. BCDA, PMCB, KPRX, TLPH, BCTX, PHXM, AEON, CYCN, CSCI, and TSBX
Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include BioCardia (BCDA), PharmaCyte Biotech (PMCB), Kiora Pharmaceuticals (KPRX), Talphera (TLPH), BriaCell Therapeutics (BCTX), PHAXIAM Therapeutics (PHXM), AEON Biopharma (AEON), Cyclerion Therapeutics (CYCN), COSCIENS Biopharma (CSCI), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry.
ZyVersa Therapeutics vs.
BioCardia (NASDAQ:BCDA) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.98 beat BioCardia's score of 0.00 indicating that ZyVersa Therapeutics is being referred to more favorably in the news media.
BioCardia received 14 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 60.71% of users gave BioCardia an outperform vote.
20.6% of BioCardia shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by insiders. Comparatively, 0.3% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 982.25%. ZyVersa Therapeutics has a consensus price target of $120.00, indicating a potential upside of 9,736.07%. Given ZyVersa Therapeutics' higher probable upside, analysts clearly believe ZyVersa Therapeutics is more favorable than BioCardia.
BioCardia has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
ZyVersa Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.
BioCardia has higher revenue and earnings than ZyVersa Therapeutics.
Summary
BioCardia beats ZyVersa Therapeutics on 9 of the 14 factors compared between the two stocks.
Get ZyVersa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZyVersa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ZVSA) was last updated on 2/22/2025 by MarketBeat.com Staff
